217 related articles for article (PubMed ID: 10488960)
1. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Alfon J; Guasch JF; Berrozpe M; Badimon L
Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Martínez-González J; Alfón J; Berrozpe M; Badimon L
Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
[TBL] [Abstract][Full Text] [Related]
3. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Kolyada AY; Fedtsov A; Madias NE
Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
[TBL] [Abstract][Full Text] [Related]
4. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Bustos C; Hernández-Presa MA; Ortego M; Tuñón J; Ortega L; Pérez F; Díaz C; Hernández G; Egido J
J Am Coll Cardiol; 1998 Dec; 32(7):2057-64. PubMed ID: 9857893
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits.
Mitani H; Egashira K; Kimura M
Pharmacol Res; 2003 Nov; 48(5):417-27. PubMed ID: 12967585
[TBL] [Abstract][Full Text] [Related]
7. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Parker RA; Huang Q; Tesfamariam B
Atherosclerosis; 2003 Jul; 169(1):19-29. PubMed ID: 12860247
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages.
Wang W; Song W; Wang Y; Chen L; Yan X
J Cardiovasc Pharmacol; 2013 Jul; 62(1):90-8. PubMed ID: 23846804
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Wagner AH; Schwabe O; Hecker M
Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
[TBL] [Abstract][Full Text] [Related]
10. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A
Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
[TBL] [Abstract][Full Text] [Related]
12. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Laufs U; La Fata V; Plutzky J; Liao JK
Circulation; 1998 Mar; 97(12):1129-35. PubMed ID: 9537338
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Kuwahara N; Sasaki S; Kobara M; Nakata T; Tatsumi T; Irie H; Narumiya H; Hatta T; Takeda K; Matsubara H; Hushiki S
Int J Cardiol; 2008 Jan; 123(2):84-90. PubMed ID: 17434618
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Asahi M; Huang Z; Thomas S; Yoshimura S; Sumii T; Mori T; Qiu J; Amin-Hanjani S; Huang PL; Liao JK; Lo EH; Moskowitz MA
J Cereb Blood Flow Metab; 2005 Jun; 25(6):722-9. PubMed ID: 15716855
[TBL] [Abstract][Full Text] [Related]
16. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J
Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313
[TBL] [Abstract][Full Text] [Related]
17. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
[TBL] [Abstract][Full Text] [Related]
19. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Heeba G; Moselhy ME; Hassan M; Khalifa M; Gryglewski R; Malinski T
Br J Pharmacol; 2009 Apr; 156(8):1256-66. PubMed ID: 19226281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
